Profil
Mann Muhsin worked as a Medical Director-Oncology Clinical Development at Halozyme Therapeutics, Inc. from 2016 to 2019.
He then worked as a Senior VP-Oncology Clinical Development at HUYA Bioscience International LLC from 2019 to 2020.
In 2021, he became the Chief Medical Officer at Medicenna Therapeutics Corp.
Dr. Muhsin earned a doctorate degree from the University of Baghdad.
Ehemalige bekannte Positionen von Mann Muhsin
| Unternehmen | Position | Ende |
|---|---|---|
| MEDICENNA THERAPEUTICS CORP. | Chief Tech/Sci/R&D Officer | 17.01.2022 |
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.04.2020 |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01.03.2019 |
Ausbildung von Mann Muhsin
| University of Baghdad | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| MEDICENNA THERAPEUTICS CORP. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
